PWMG
ALXN

Prestige Wealth Management Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Prestige Wealth Management Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-58
Closed -$11K – 1076
2021
Q2 		$11K Buy
58
+8
+16% +$1.37K ﹤0.01% 474
2021
Q1 		$8K Sell
50
-35
-41% -$5.41K ﹤0.01% 537
2020
Q4 		$13K Buy
85
+73
+608% +$9.38K ﹤0.01% 417
2020
Q3 		$1K Hold
12
– – ﹤0.01% 866
2020
Q2 		$1K Sell
12
-16
-57% -$1.7K ﹤0.01% 872
2020
Q1 		$3K Buy
+28
New +$2.75K ﹤0.01% 607
2019
Q1 		– Sell
-105
Closed -$10K – 1237
2018
Q4 		$10K Buy
+105
New +$12.4K 0.01% 444

Other funds holding ALXN

Brinker Capital Investments
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TD Ameritrade Investment Management
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Prestige Wealth Management Group's ALXN Position: Q3 2021 in Review

Prestige Wealth Management Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 58 shares — an estimated $11K sold.

Prestige Wealth Management Group first reported a position in ALXN in Q4 2018 and held it in 7 quarters. The position peaked at $13K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Prestige Wealth Management Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Prestige Wealth Management Group sold 58 Alexion Pharmaceuticals shares in Q3 2021, an estimated $11K.
  • Prestige Wealth Management Group first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 7 quarters.
  • Prestige Wealth Management Group's Alexion Pharmaceuticals position peaked at $13K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Prestige Wealth Management Group's 13F filing for Q3 2021, filed 12 Nov 2021.